Acad Pediatr by Irving, Stephanie A. et al.
Human Papillomavirus Vaccine Coverage and Prevalence of 
Missed Opportunities for Vaccination in an Integrated Healthcare 
System
Stephanie A. Irving, MHS,
Center for Health Research, Kaiser Permanente Northwest, Portland, Ore
Holly C. Groom, MPH,
Center for Health Research, Kaiser Permanente Northwest, Portland, Ore
Shannon Stokley, DrPH,
Immunization Services Division
Michael M. McNeil, MD, MPH,
Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Ga
Julianne Gee, MPH,
Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Ga
Ning Smith, PhD, and
Center for Health Research, Kaiser Permanente Northwest, Portland, Ore
Allison L. Naleway, PhD
Center for Health Research, Kaiser Permanente Northwest, Portland, Ore
Abstract
BACKGROUND: Human papillomavirus (HPV) vaccination has been recommended in the 
United States for female and male adolescents since 2006 and 2011, respectively. Coverage rates 
are lower than those for other adolescent vaccines. The objective of this study was to evaluate an 
assessment and feedback intervention designed to increase HPV vaccination coverage and 
quantify missed opportunities for HPV vaccine initiation at preventive care visits.
METHODS: We examined changes in HPV vaccination coverage and missed opportunities within 
the adolescent (11–17 years) population at 9 Oregon-based Kaiser Permanente Northwest 
outpatient clinics after an assessment and feedback intervention. Quarterly coverage rates were 
calculated for the adolescent populations at the clinics, according to age group (11–12 and 13–17 
years), sex, and department (Pediatrics and Family Medicine). Comparison coverage assessments 
were calculated at 3 nonintervention (control) clinics. Missed opportunities for HPV vaccine 
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initiation, defined as preventive care visits in which a patient eligible for HPV dose 1 remained 
unvaccinated, were examined according to sex and age group.
RESULTS: An average of 29,021 adolescents were included in coverage assessments. Before the 
intervention, 1-dose and 3-dose quarterly coverage rates were increasing at intervention as well as 
at control clinics in both age groups. Postimplementation quarterly trends in 1-dose or 3-dose 
coverage did not differ significantly between intervention and control clinics for either age group. 
One-dose coverage rates among adolescents with Pediatrics providers were significantly higher 
than those with Family Medicine providers (56% vs 41% for 11- to 12-year-old and 82% vs 69% 
for 13- to 17-year-old girls; 55% vs 40% for 11- to 12-year-old and 78% vs 62% for 13- to 17-
year-old boys).
CONCLUSIONS: No significant differences in HPV vaccine coverage were identified at 
intervention clinics. However, coverage rates were increasing before the start of the intervention 
and might have been influenced by ongoing health system best practices. HPV vaccine coverage 
rates varied significantly according to department, which could allow for targeted improvement 
opportunities.
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THE ADVISORY COMMITTEE on Immunization Practices (ACIP) recommendation for 
human papillomavirus (HPV) vaccination has been in place since 2006 for girls and 2011 for 
boys; however, coverage rates have been substantially lower than rates for other adolescent-
recommended vaccines. According to data from the 2015 National Immunization Survey-
Teen, only 63% of 13- to 17-year-old girls and 50% of 13- to 17-year-old boys initiated the 
HPV vaccine series. In comparison, coverage for 2 other adolescent vaccines, tetanus-
diphtheria-acellular pertussis (Tdap) and meningococcal conjugate vaccine (MenACWY), 
which were added to the adolescent vaccine schedule in 2005, has climbed to 87% and 81%, 
respectively.1
High Tdap vaccine coverage is generally attributed to the mandates for Tdap vaccine receipt 
before secondary school entry in most (47 of 50) states.2 School mandates for MenACWY 
vaccination exist in 28 states; these mandates might have played a part in coverage rates for 
the vaccine reaching the Healthy People 2020 goal of 80%, although national estimates 
remain lower than those for Tdap.3,4 Because of the prevalence of HPV infection in the US 
population, and the opportunity for reduction of HPV-related cancers, leading health 
organizations have made increasing HPV vaccination rates a priority and have produced and 
supported use of provider resources specifically focused on increasing HPV vaccination 
coverage.3,5,6 Available resources focus on the importance of a strong provider 
recommendation for HPV vaccination at ages 11 or 12 years, and provide guidance on how 
to communicate effectively with vaccine-hesitant parents and teens. Also among the 
suggested strategies are assessment and feedback interventions, in which health educators 
engage with health care providers to discuss HPV vaccination rates specific to their patient 
population and identify opportunities for improving vaccine delivery practices.7 Past efforts 
to use assessment and feedback have had some success within individual clinic settings. 
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However, little is known about its application and use in integrated health care delivery 
systems, which might have consistent standards and policies in place.8,9
Kaiser Permanente Northwest (KPNW), which serves approximately 570,000 patients in 
Oregon and southwest Washington, is an example of an integrated health care delivery 
system that uses a variety of evidence-based practices for improving adolescent vaccination 
rates. However, HPV initiation rates within KPNW are far lower than those for other 
adolescent vaccines. In an effort to examine the effect of assessment and feedback on HPV 
vaccination rates in the KPNW population, a quasiexperi-mental intervention study entitled 
‘Boosting Recommended Adolescent Vaccination in Oregon’ (BRAVO) was implemented in 
select Oregon clinics in 2015 to 2016.
The primary study objective of BRAVO was to evaluate an assessment and feedback 
intervention designed to increase HPV vaccination coverage and reduce missed 
opportunities for HPV vaccine initiation at preventive care visits compared with standard of 
care. A secondary study objective was to assess the effect of the intervention according to 
clinical department (Pediatrics and Family Medicine).
Methods
All BRAVO protocols, materials, and study procedures were approved by the KPNW 
institutional review board.
Study Period And Population
Adolescents aged 11 to 17 years, with at least 6 months of continuous health plan enrollment 
and assigned to either a Pediatrics or Family Medicine provider at 1 of the participating 
clinics, were included in the study. Intervention clinics included the 9 largest KPNW clinics 
in the state of Oregon, which included approximately 150 physicians and their health care 
teams. Only Oregon-based clinics were included because of the partnership with the Oregon 
Immunization Program (OIP) whose jurisdiction was limited to Oregon. For comparison 
purposes, we included adolescent populations in 3 KPNW clinics in southwest Washington, 
which served as our nonrandomized convenience control sample. Intervention as well as 
control clinics had best practices in place at intervention onset: standing orders for 
vaccination if eligible, walk-in vaccination, electronic medical record prompts, vaccination 
reminder birthday letters, and vaccine coverage reports of Healthcare Effectiveness Data and 
Information Set measures.
The BRAVO intervention period lasted from April 2015 through June 2016. A baseline data 
collection period—April 2011 through March 2015—was included to evaluate trends in 
HPV vaccine coverage and missed opportunities at preventive care visits that predated the 
intervention period and draw conclusions regarding the effectiveness of the intervention.
Intervention
We implemented a provider-focused assessment and feedback intervention to promote HPV 
vaccination in our intervention clinics. In partnership with the Centers for Disease Control 
and Prevention, the OIP, and KPNW’s health plan leadership, we developed a 30-minute 
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education session combining information on HPV infection, parental communication 
strategies,10 and clinic-and department-specific coverage and missed opportunity data.
Baseline education sessions were presented to Family Medicine and Pediatrics departments 
in 9 KPNW clinics in April 2015; the content of the education sessions has been described 
elsewhere in detail.11 Briefly, at each of these baseline education sessions a study team 
member paired with a health educator from the OIP to deliver the intervention. The study 
team member presented information on HPV disease and HPV vaccination using the Centers 
for Disease Control and Prevention-developed “You are the Key to Cancer Prevention” 
materials, as well as vaccine coverage and missed opportunity for HPV vaccine initiation at 
preventive care visit data tailored according to clinical department (Pediatrics and Family 
Medicine). The OIP health educator then led the health care teams (physicians, nurses, 
medical assistants, and department administrators) in participatory dialogue, reviewing 
communication strategies related to HPV vaccination and department-specific challenges to 
HPV vaccine communication.
The HPV vaccination data presented during the meetings, as well as provider-specific 
population reports, were distributed to the health care teams via paper copies after the 
meetings in the form of Assessment Reports; the provider- and clinical department-specific 
Assessment Reports were sent to the health care teams electronically and via paper copies 
on a quarterly basis for the duration of the study period. The Assessment Reports included: 
1) HPV vaccine coverage rates for the 11- to 17-year-old populations paneled to the specific 
clinical department and provider, compared with rates of MenACWY and Tdap in the same 
populations, and 2) missed opportunities for HPV vaccination at vaccine-eligible preventive 
care visits. Calculation of coverage and missed opportunities are described in more detail 
under Data Assessments.
In January 2016, the research team returned to all clinical departments for follow-up visits to 
discuss new and remaining barriers to HPV vaccination within their patient populations, 
have staff share experiences using the communication strategies discussed at the baseline 
sessions, and present HPV coverage and rates of missed opportunities for HPV vaccine 
initiation at preventive care visits, with data plotted for the full 2015 calendar year.
Data Sources
Data were collected using quarterly, cross-sectional population assessments. All information 
on administered vaccines and preventive care visit dates were obtained from the KPNW 
electronic health record (EHR). KPNW has bidirectional data exchange with ALERT-IIS, 
the state of Oregon immunization information system (IIS), which captures data on vaccines 
given outside of the health plan.12
Data Assessments
Coverage was defined as the proportion of adolescents assigned to primary care providers at 
the specific clinic and department on the assessment date who had received the HPV vaccine 
as of that date. Coverage estimates were created for 2 age groups: 11 to 12 years and 13 to 
17 years. Coverage was calculated for ≥1 dose (referred to as 1-dose coverage), and for ≥3 
doses (referred to as 3-dose coverage); vaccine receipt was valid only if the ACIP 
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recommended timing elapsed between vaccine doses.13 Coverage was calculated separately 
for boys and girls.
Missed opportunities for HPV vaccine initiation at preventive care visits were defined as any 
preventive care visit in the previous 3 months in which an adolescent was eligible for the 
first dose of HPV vaccine, but did not receive it. Anticipating differences according to age, 
missed opportunities were calculated for 2 age groups: 11 to 12 years and 13 to 17 years. 
Preventive care visits were identified using International Classification of Diseases-Ninth 
Revision codes for routine child health exam (V20.2), routine medical exam (V70.0), and 
other medical exam for administrative purposes (V70.3). Missed opportunities were 
restricted to preventive care visits on the basis of consistent, strong feedback from clinical 
staff.
Statistical Analysis
Primary analyses consisted of HPV vaccine coverage (1-dose and 3-dose) and rates of 
missed opportunities according to age group and sex. Secondary analyses explored 
differences in 1-dose HPV vaccine coverage according to Pediatrics and Family Medicine 
departments.
Using segmented regression to generate interrupted time series models,14 we estimated the 
change in level and trend in the HPV vaccine coverage rates and missed opportunities after 
implementation of the intervention, while controlling for the secular trend in the 
preintervention time period. The study period was divided into 2 segments: preintervention 
period (March 2011–March 2015) and intervention period (April 2015–June 2016). The 
outcomes were aggregated and presented quarterly. Among boys, the first 4 quarters—before 
the ACIP recommendation for boys—were dropped from analysis because of low vaccine 
uptake rates.13
The Durbin–Watson statistic was used to test for serial autocorrelation of error terms in the 
regression model.15 Because of the nature of the quarterly data, error terms of 4 quarters 
were evaluated for autocorrelation to account for seasonality. Stepwise autoregression, 
conducted using the maximum likelihood method with back step option, corrected for 
autocorrelation when detected. All final models had a Durbin–Watson statistic value close to 
the preferred value of 2. SAS version 9.4 (SAS Institute Inc, Cary, NC) was used for all 
analyses. A P value < .05 was considered significant.
Results
The adolescent patient populations of each intervention clinic ranged from 1600 to 6198 (as 
of June 2016 data collection). The average number of adolescents included in each cross-
sectional quarterly vaccine coverage assessment was 29,021. Most adolescents (77%) had 
Pediatrics-based primary care providers, rather than Family Medicine providers.
Throughout the study period, there was a general upward trend in HPV vaccine coverage in 
both age groups and both sexes. At the conclusion of the BRAVO intervention period 1-dose 
HPV vaccine coverage was 53% and 52% among 11- to 12-year-old girls and boys at the 
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intervention clinics, respectively. At the same time point, 13- to 17-year-old 1-dose HPV 
vaccine coverage was 79% and 74% among girls and boys at the intervention clinics, 
respectively (Fig. 1).
One-dose HPV vaccine coverage varied significantly according to clinical department; at the 
conclusion of the BRAVO intervention, 1-dose coverage among 11- to 12- year-old girls was 
56% and 41% according to department (Pediatrics compared with Family Medicine, P < .
001; data not shown). One-dose coverage among 11- to 12-year-old boys was 55% and 40%, 
respectively (department comparison, P < .001). Patterns were similar among 13- to 17-year-
old girls and boys, with statistically significantly higher 1-dose coverage rates in Pediatrics.
Although rates were lower, patterns for 3-dose HPV vaccine coverage were similar to those 
for 1-dose coverage. HPV vaccine 3-dose coverage at the conclusion of the BRAVO 
intervention period was 14% and 11% among 11- to 12-year-old girls and boys, respectively, 
and 57% and 46% among 13- to 17-year-old girls and boys, respectively (Fig. 2).
In our primary analysis, we observed statistically significant increasing coverage trends 
among girls and boys in the quarters preceding the BRAVO intervention, at intervention as 
well as control clinics; this increasing trend was present for 1-dose as well as 3-dose HPV 
vaccine coverage, and for 11- to 12- and 13- to 17-year-old age groups (Table 1). After 
implementation of the BRAVO intervention, the only statistically significant positive change 
in quarterly trend was seen among 11- to 12-year-old girls at intervention as well as control 
clinics, for 3-dose vaccine coverage (0.82% and 1.59% coverage increases on average per 
quarter, respectively, compared with the trend in the preintervention period). The change in 
trend was significantly greater at control clinics, compared with intervention clinics (P = .
002). No other control versus intervention clinic comparisons of postintervention changes in 
trend were statistically significant. Among most age and sex groups, 1-dose as well as 3-
dose HPV vaccine coverage was increasing at a greater rate at intervention clinics, compared 
with control clinics, before the BRAVO intervention (Table 1).
In secondary analyses, we compared trends in 1-dose HPV vaccine coverage across 
Pediatrics and Family Medicine departments. Among girls, coverage among 11- to 12- and 
13- to 17-year-old girls with Pediatrics-based providers was 12 and 13 percentage points 
higher at baseline, respectively, compared with those with Family Medicine providers (P < .
001 and P < .001). At baseline, 1-dose coverage was also higher among 11- to 12- and 13- to 
17-year-old boys with Pediatrics providers, compared with those with Family Medicine 
providers, but the differences did not reach statistical significance (14 and 13 percentage 
points higher, respectively, P = .056 and P = .163, respectively). The differences in coverage 
rates remained consistent over the study period for both sexes. The difference in trends in 1-
dose coverage did not vary between the 2 departments over the study period for either sex.
In primary analyses we examined rates of missed opportunities for HPV vaccine series 
initiation (ie, first dose HPV vaccination) according to age group and sex. We observed a 
decreasing trend in missed opportunities among 11- to 12-year-old boys and girls before the 
implementation of the BRAVO intervention (Table 2). Among the 13- to 17-year-old age 
group, the quarterly trend for missed opportunities was increasing before the intervention, 
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but only reached statistical significance among boys. After implementation of the BRAVO 
intervention, there was a statistically significant decrease in the quarterly trend of missed 
opportunities among 13- to 17-year-old girls, at intervention clinics compared with control 
clinics (P = .019). No additional intervention versus control clinic comparisons reached 
statistical significance (Table 2).
Discussion
The BRAVO project was an effort to examine the effect of assessment and feedback on HPV 
vaccination rates and vaccine initiation within an integrated health care delivery system. 
Over the study period, before as well as after the intervention, we identified significant 
increases in vaccination coverage across adolescent age groups. However, the intervention 
did not result in significantly different increases in HPV vaccine coverage at intervention 
clinics, compared with control clinics. After the intervention, there was a significant 
decrease in the rate of missed opportunities for vaccine initiation at preventive care visits 
among older female adolescents, significant changes were not identified in other age/gender 
groups.
Assessment and feedback has been effective at improving vaccination coverage in various 
settings and continues to be a recommended strategy for improving HPV vaccination rates.7 
Recent reviews have also mentioned that interventions to improve HPV vaccination 
coverage are most effective when implemented in combination with other recommended 
strategies, reinforcing the idea that multifaceted provider- and community-level engagement 
approaches have the greatest potential for increasing vaccine coverage.16-18
The BRAVO intervention was an effort to improve HPV vaccination coverage in an 
integrated health system, where immunization best practices are deeply embedded. From the 
use of an EHR, bidirectional exchange with the state IIS, reminder and recall systems 
generating letters to parents of children due for vaccinations, to the availability of walk-in 
vaccination opportunities, KPNW uses the full range of recommended clinic-based 
strategies.6 KPNW HPV vaccination rates have been consistently trending upward since 
2012, possibly because of the ongoing presence of these strategies, but this newly added 
intervention did not appear to contribute any added increase to that upward trend.
It is important to mention that HPV vaccination rates in this integrated health system were 
much higher than national averages; compared with 2015 national estimates,1 KPNW had 
16% and 24% higher HPV vaccine initiation rates among 13- to 17-year-old girls and boys, 
respectively. Additionally, our data show consistent significant increases in HPV vaccine 
coverage before implementation, and a slowing of that increase around the onset of the 
project. The lack of intervention effect might in fact be a result of health care system 
saturation, in that the breadth of immunization strategies in place at KPNW before the 
intervention had resulted in the highest HPV coverage rates possible in this setting, resulting 
in no effect from BRAVO. Furthermore, 1-dose HPV vaccination rates were lower than for 
the Tdap and MenACWY rates in the same population, yet the health system’s strategies 
already in place combined with this HPV-focused intervention were not sufficient to bring 
HPV vaccination rates on par with those for the other adolescent-recommended vaccines. 
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This suggests that the current recommended clinical strategies are not fully addressing the 
barriers to HPV vaccination present in the United States.19 Attitudes toward HPV 
vaccination might be intrinsically different than those toward other adolescent-recommended 
vaccines, and might require novel recommendation approaches.
An interesting finding from this study was that HPV vaccination rates were significantly 
higher among Pediatrics populations, compared with Family Medicine populations, in this 
health care system. This finding is consistent with significantly higher rates of adolescent 
and HPV vaccine recommendations among pediatricians, compared with family physicians, 
published previously.20-22 Although coverage in both clinical department types increased 
across our study period at similar rates, the significant difference in coverage rates remained. 
Policies and clinical priorities are the same across departments at KPNW, so whether this 
finding is attributable to differences among the adolescent populations, the parents who 
choose one provider type over another, or among the health care providers working in the 
respective departments is unknown. Oster and colleagues reported significant differences in 
sources of vaccine recommendations reported according to provider type,20 but because the 
BRAVO intervention targeted both departments, and because KPNW policies and resources 
span departments, differences in resources should not have been a key factor in this provider 
population. Opportunities for additional interventions, targeted to specific departments or 
provider types, are worth examining more closely.
Missed opportunities for first-dose HPV vaccination were common, although this analysis 
was limited to preventive care visits. Our definition of a missed opportunity required access 
to EHR data, which is different than many other studies that publish rates of missed 
opportunities on the basis of vaccination data contained in IIS,23 or in claims data.24 
Although there are limited data on missed opportunities using EHR data, one such study 
reported that approximately 60% of adolescents attending a preventive care visit have a 
missed opportunity for HPV vaccine.25 This was consistent with our finding of a 67% 
missed opportunity rate among girls 13 to 17 years old. The slight downward trend in missed 
opportunities observed in the 13- to 17-year-old girls in intervention clinics might suggest 
that the tools provided in this intervention were helpful to providers in either initial 
vaccination of new female patients, or catch-up vaccination for those who had previously 
refused. However, this effect was not observed among younger girls or either of the male age 
groups. A recent study by Fiks et al enlisted pediatricians in a Maintenance of Certification 
program targeting HPV missed opportunities.26 This study examined well as well as sick 
visits, and did not separate male and female visits. The authors reported an increase in first-
dose HPV vaccine capture, relative to nonparticipating clinicians, at preventive care visits. 
Differences that might account for this finding, relative to the BRAVO results, might include 
the clinician buy-in created by the certification requirement and the collective identification 
of improvement goals. Health system differences and best practices, as well as differences in 
rates of missed vaccine opportunities at study onset could have also affected the difference 
in study findings. The study by Fiks et al as well as the BRAVO project show the utility of 
EHR data for timely feedback of missed opportunity data to clinicians.
A strength of the BRAVO project was the ability to examine vaccine initiation rates over 
time among 11- to 12-year-old patients, the age group for which vaccine initiation is 
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recommended, in addition to the older age group. The plateauing of 3-dose coverage among 
11- to 12-year-old patients at 10% to 15% might indicate the need for enhanced strategies 
focusing on timely vaccine initiation. An additional study strength included the scalable 
nature of the project within the health system framework; partnering with health educators 
from the state health department and using existing clinical meeting times reduced the 
burden to study as well as clinical staff. The use of EHR data allowed for near real-time data 
collection and distribution.
An important limitation of this study includes that many active efforts to improve HPV 
vaccination were already in place before implementing this intervention, making it very 
difficult to tease out which factors might have been associated with the trend in increasing 
rates. Additionally, differences between intervention and control clinics might be in part 
because of differences at the state level, because our intervention and control sites were in 
different states, and not randomly assigned. However, because all clinics were part of the 
same health care system, with the same policies and practices around HPV vaccination, 
there is no expectation that this would lead to coverage differences. An additional limitation 
of the project was the restriction of the missed opportunity analysis to preventive care visits. 
Acute visits were excluded from this analysis a priori, on the basis of previous work in our 
population showing rates of missed opportunities in this population at these visits 
consistently near 100%. Feedback from clinician partners during planning indicated that this 
feedback would not be useful for providers, who are aware that vaccination does not take 
place at these visits, and do not believe that vaccination is appropriate at these visits. Rather, 
BRAVO decided to focus on preventive care visits, at which vaccination should take place. 
The authors believed that communicating missed opportunities at these visits exclusively 
was more meaningful for providers. Finally, some adolescents at each quarter might have 
only recently turned 11 years old, limiting the window for vaccination and possibly 
increasing the proportion unvaccinated in that age group.
In conclusion, HPV vaccine coverage was increasing in this integrated care system 
population before the start of this intervention, with no significant changes in quarterly 
trends after the intervention. Lack of significant coverage increases after this intervention is 
another example of the ongoing challenge of HPV vaccination in the United States. The 
modest coverage improvements observed in our study population, and the plateau in rates, 
reflect the national trend in HPV vaccine coverage, implying these challenges are a 
widespread issue.1 Because of the multifaceted immunization strategies ongoing within the 
KPNW system, consistent with current recommended practice,19 these results suggest that 
the desired increases in HPV vaccine coverage might require reaching parents before their 
HPV vaccination decision-making begins, or clinic-based interventions targeted to specific 
provider types.
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What’s New
In a quasiexperimental study, conducted in a large health system, the effect of an 
intervention of assessment and feedback of human papillomavirus (HPV) vaccination 
coverage was compared with standard of care and no significant increase in HPV 
vaccination coverage was found in intervention clinics compared with control clinics; 
missed opportunities for vaccination during preventive care visits declined only for girls 
age 13 to 17 years. Increasing HPV vaccination coverage in a large health system with a 
history of implementing recommended best practices continues to be challenging.
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Figure 1. 
One (≥7) dose human papillomavirus (HPV) vaccination coverage rates according to age 
group, sex, and clinic type (intervention or control). Vertical line marks start of Boosting 
Recommended Adolescent Vaccination in Oregon (BRAVO) intervention period.
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Figure 2. 
Three (≥3) dose human papillomavirus (HPV) vaccination coverage rates according to age 
group, sex, and clinic type (intervention or control). Vertical line marks start of Boosting 
Recommended Adolescent Vaccination in Oregon (BRAVO) intervention period.
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